Anyone posting a threat especially against a law enforcement officer or politician will be banned
Pfizer announced Friday that a recent trial study revealed its antiviral pill Paxlovid was not effective at preventing Covid-19 infection in adults who had been exposed to the virus through household contact. more and more reports of patients taking Pfizer’s antiviral pill experienced a second round of Covid-19 shortly after recovering. Experts are still investigating the causes and they are baffled.
Scientific documentation about post-Paxlovid relapse has been available since last fall. Pfizer’s application to the FDA for emergency use authorization of Paxlovid stated that in the placebo-controlled clinical trial — which included 2,246 participants — “several subjects appeared to have a rebound in SARS-CoV-2 RNA levels around Day 10 or Day 14” after beginning treatment, NBC reported.
Following this report, Pfizer released a statement admitting that it failed to reduce the risk of confirmed and symptomatic COVID-19 infection in adults living with someone who had been exposed to the virus.